ALX Oncology Holdings Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-02-19$2.60 RISE2026-04-29$1.58 PEAK2026-05-06$2.09 76d | -39.2% 69d | Missed | Missed | — | — | +32.3% 7d | Missed |
DROP2025-10-03$2.18 RISE2026-01-06$1.08 PEAK2026-02-19$2.60 139d | -50.5% 95d | Missed | Missed | — | — | +140.7% 44d | Missed |
DROP2025-10-03$2.18 RISE2025-11-06$1.18 PEAK2026-02-04$2.01 124d | -45.9% 34d | Missed | Missed | — | — | +70.3% 90d | Missed |
DROP2025-03-06$1.31 RISE2025-06-27$0.41 PEAK2025-09-22$1.27 200d | -69.0% 113d | Missed | Missed | — | — | +212.8% 87d | Missed |
DROP2025-01-22$1.80 RISE2025-05-21$0.41 PEAK2025-08-18$0.97 208d | -77.3% 119d | Missed | Missed | — | — | +137.4% 89d | Missed |
DROP2024-07-16$8.13 RISE2024-11-20$1.21 PEAK2024-12-23$1.87 160d | -85.1% 127d | Missed | Missed | — | — | +54.5% 33d | Missed |
DROP2024-02-15$16.79 RISE2024-04-02$10.72 PEAK2024-05-07$17.56 82d | -36.2% 47d | Missed | Missed | — | — | +63.8% 35d | Missed |
DROP2023-06-15$9.56 RISE2023-08-28$4.19 PEAK2023-11-20$9.80 158d | -56.2% 74d | Missed | Missed | — | — | +133.9% 84d | Missed |
DROP2022-12-05$11.84 RISE2023-04-04$4.37 PEAK2023-06-15$9.56 192d | -63.1% 120d | Missed | Missed | — | — | +118.8% 72d | Missed |
DROP2022-08-15$15.14 RISE2022-09-27$9.48 PEAK2022-11-01$12.89 78d | -37.4% 43d | Missed | Missed | — | — | +36.0% 35d | Missed |
DROP2022-03-18$20.00 RISE2022-06-16$5.89 PEAK2022-08-15$15.14 150d | -70.5% 90d | Missed | Missed | — | — | +157.0% 60d | Missed |
DROP2021-09-27$76.87 RISE2022-02-03$13.65 PEAK2022-03-18$20.00 172d | -82.2% 129d | Missed | Missed | — | — | +46.5% 43d | Missed |
DROP2021-03-17$80.76 RISE2021-07-15$52.51 PEAK2021-09-16$80.91 183d | -35.0% 120d | Missed | Missed | — | — | +54.1% 63d | Missed |
DROP2021-03-01$87.68 RISE2021-05-25$52.20 PEAK2021-08-17$68.49 169d | -40.5% 85d | Missed | Missed | — | — | +31.2% 84d | Missed |
DROP2020-08-17$47.10 RISE2020-10-01$34.11 PEAK2020-12-10$112.26 115d | -27.6% 45d | Missed | Missed | — | — | +229.1% 70d | Missed |
No scored news yet for a sentiment trend.
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Moby summary of ALX Oncology Holdings Inc.'s Q1 2026 earnings call
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call May 8, 2026 8:30 AM EDTCompany ParticipantsJason Lettmann - CEO & DirectorBarbara Klencke -...
Presentation Operator MessageOperator Greetings, and welcome to the ALX Oncology First Quarter 2026 Financial Results Conference and webcast. [Operator Instructions] Please note, this conference is...
2026-05-08. The following slide deck was published by ALX Oncology Holdings Inc.
ALX Oncology (NASDAQ:ALXO) executives used the company’s first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continue
ALX Oncology (NASDAQ:ALXO) executives used the company’s first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continue
ALX Oncology beat Q1 2026 estimates with a narrower loss. Promising ESMO data showed 60% response in HER2-positive breast cancer. Strong $169M cash runway through 2028.
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer - - Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab
N A S D A Q - A L X O Q1 202C Earnings Presentation May 2026 © ALX Oncology Inc. All rights reserved. ...
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 68.75 percent increase over losses of $(0.48) per share
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the randomized ASPEN-06 trial in HER2-positive gastric cancer, which indicated CD47 expression could potentially serve as an important predictive biomarker of evorpacept activity - - ALX Oncology will host a webcast on May 8 to report first quarter 2026 financial results; breast cancer expert will discuss
ALX Oncology Holdings Inc:ALX Oncology's evorpacept in combination with zanidatamab generates promising, durable response in patients with advanced HER2-positive breast cancer and high CD47...
The Phase 1b/2 open-label, multi-center clinical trial (NCT05027139) evaluating evorpacept plus zanidatamab included patients with heavily pre-treated HER2-positive mBC (median of five prior HER2-targeted therapies), all
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that new data from the Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz P
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 -SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 800,000 shares of ALX Oncology’s common stock to Jeff Knight, M.P.H., Chief Developmen
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALXO | +12.43% | -10.38% | +68.14% | +290.95% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +9.46% | -4.66% | +71.58% | +278.26% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 1.59M | $3.18M | 0.00% | Added+148.0% | 2026-03-31 |
| RenTech | quant | 732.6K | $1.47M | 0.00% | Added+73.2% | 2026-03-31 |
| StateStreet | passive | 175.8K | $352.54K | 0.00% | Added+41.5% | 2026-03-31 |
| Citadel | multi-strat | 41.1K | $82.40K | 0.00% | Added+103.3% | 2026-03-31 |
| FidelityFMR | fundamental | 13.0K | $26.04K | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-11upcoming | -0.16 | — | — |
| 2026-05-08 | -0.16 | -0.15 | +6.82% |
| 2026-02-27 | -0.32 | -0.37 | -15.54% |
| 2025-11-07 | -0.37 | -0.41 | -10.07% |
| 2025-08-12 | -0.31 | -0.44 | -43.10% |
| 2025-05-08 | -0.31 | -0.48 | -54.47% |
| 2025-03-06 | -0.64 | -0.55 | +14.26% |
| 2024-11-07 | -0.66 | -0.58 | +11.42% |
| 2024-08-08 | -0.70 | -0.62 | +12.08% |
| 2024-05-09 | -0.71 | -0.71 | -0.28% |
| 2024-03-07 | -0.84 | -0.79 | +5.76% |
| 2023-11-13 | -0.89 | -1.24 | -38.87% |
| 2023-08-10 | -0.86 | -0.83 | +3.37% |
| 2023-05-11 | -0.80 | -0.74 | +8.44% |
| 2023-03-09 | -0.88 | -0.75 | +14.11% |
| 2022-11-08 | -0.74 | -0.87 | -17.73% |